Continuous Glucose Monitoring in Type 1 Diabetes, Type 2 Diabetes, and Diabetes During Pregnancy: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

Mar 6, 2025Diabetes technology & therapeutics

Continuous Glucose Monitoring in Type 1, Type 2, and Pregnancy-Related Diabetes: A Review and Analysis of Controlled Trials

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

A total of 64 randomized controlled trials were analyzed, indicating that continuous glucose monitoring (CGM) is superior to self-monitoring of blood glucose (BGM) in various diabetes populations.

In type 1 diabetes (T1D), CGM resulted in a reduction of glycated hemoglobin (HbA1c) by an average of 0.24%.
CGM significantly decreased time below range (TBR) for glucose levels under 70 mg/dL and under 54 mg/dL.
CGM also reduced time above range (TAR) for glucose levels exceeding 180 mg/dL and 250 mg/dL.
For type 2 diabetes (T2D), CGM led to a greater HbA1c reduction of 0.40% compared to BGM.
CGM improved time in range (TIR) for glucose levels between 70-180 mg/dL in both T1D and T2D.
In diabetes during pregnancy (DiP), CGM improved TIR for glucose levels between 63-140 mg/dL, but no significant benefits were observed for HbA1c.

AI simplified

Continuous glucose monitoring (real-time CGM [RT-CGM] and retrospective [professional] CGM [non-RT-CGM]) is an emerging tool to assess glucose levels and variability. We performed a meta-analysis of randomized controlled trials (RCTs) to assess the effect of RT/non-RT-CGM on type 1 (T1D), type 2 (T2D), and diabetes in pregnancy (DiP) compared with self-monitoring of blood glucose (BGM).We searched PubMed/EMBASE/Cochrane Central Register of Controlled Trials until October 2024. The coprimary outcomes were the weighted mean change differences (WMCDs and absolute differences) from baseline in glycated hemoglobin (HbA1c) and in time in range (TIR%), time below range (TBR%), and time above range (TAR%).A total of 64 RCTs were analyzed: (1) RT-CGM/T1D: CGM was superior to BGM for HbA1c reduction (WMCD -0.24, 95% confidence interval [CI]: -0.35; -0.14,= 71%), decrease in TBR <70 mg/dL (WMCD -2.41, 95% CI: -3.46; -1.35,= 96%), decrease in TBR < 54 mg/dL (WMCD -1.18 95% CI: -1.9; -0.47,= 97%), decrease in TAR >180 mg/dL (WMCD -2.99, 95% CI: -5.28; -0.71,= 92%), decrease in TAR >250 mg/dL (WMCD -3.99, 95% CI: -5.76; -2.21,= 92%), and increase in TIR 70-180 mg/dL (WMCD 5.57, 95% CI: 4.13; 7.01,= 84%); (2) RT-CGM/T2D: CGM was superior to BGM for HbA1c reduction (WMCD -0.40, 95% CI: -0.55; -0.24,= 52%), decrease in TAR > 180 mg/dL (WMCD -6.32, 95% CI: -9.87; -2.78,= 84%), decrease in TAR > 250 mg/dL (WMCD -5.73, 95% CI: -8.96; -2.49,= 89%), and increase in TIR 70-180 mg/dL (WMCD 5.46, 95% CI: 2.76; 8.16,= 69%); (3) RT-CGM/DiP: CGM was superior to BGM for TIR 63-140 mg/dL (WMCD: 17.77, 95% CI: 4.17; 31.36,= 92%). No benefit was shown for HbA1c, TBR < 63 mg/dL, TAR > 140 mg/dL, and most of the maternal and neonatal outcomes of interest; (4) Non-RT CGM: HbA1c significantly decreased with non-RT CGM compared with BGM in T2D (WMCD -0.35, 95% CI: -0.5; -0.2,= 19%).In T1D and T2D, RT-CGM decreased HbA1c and increased time in target range for glycemia (70-180 mg/dL) while decreasing time spent in hypoglycemia (T1D) and time in hyperglycemia (T1D, T2D). Background: Methods: Results: Discussion: I I I I I I I I I I I I2 2 2 2 2 2 2 2 2 2 2 2

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Continuous Glucose Monitoring in Type 1 Diabetes, Type 2 Diabetes, and Diabetes During Pregnancy: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief